• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CXS
Click for more information
0.00% 70.0¢

CHEMGENEX PHARMACEUTICALS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
CXSSuspension at close of trading 21/6/11PRICE SENSITIVE21/06/11
CXSNotice of Compulsory AcquisitionPRICE SENSITIVE14/06/11
CXSNotice of Variation of Offer: Extension of Offer PeriodPRICE SENSITIVE14/06/11
CXSNotice Under Sec 630(3) - Status of Defeating ConditionsPRICE SENSITIVE06/06/11
CXSNotice under Sec 650F re Cephalon T/OPRICE SENSITIVE01/06/11
CXSExtension of Office PeriodPRICE SENSITIVE27/05/11
CXSNotice under Section 650F of Corps ActPRICE SENSITIVE27/05/11
CXSCephalon CXS Holdings PL Notice of AcceptancesPRICE SENSITIVE27/05/11
CXSSupplementary Bidder's StatementPRICE SENSITIVE20/05/11
CXSVariation of Takeover BidPRICE SENSITIVE13/05/11
CXSSupplementary Bidder's StatementPRICE SENSITIVE04/05/11
CXSFirst Supplementary Bidder's StatementPRICE SENSITIVE29/04/11
CXSOff market takeover bid by CephalonPRICE SENSITIVE27/04/11
CXSBidder's Statement and Target's StatementPRICE SENSITIVE13/04/11
CXSCephalon UpdatePRICE SENSITIVE30/03/11
CXSCephalon Launches Takeover BidPRICE SENSITIVE29/03/11
CXSTrading HaltPRICE SENSITIVE25/03/11
CXSHalf Yearly Report and AccountsPRICE SENSITIVE18/02/11
CXSChemGenex to Align European and US Regulatory StrategiesPRICE SENSITIVE05/01/11
CXSAwarded U.S. Therapeutic Discovery grantPRICE SENSITIVE02/11/10
CXSConvertible Note Issued to Cephalon, IncPRICE SENSITIVE22/10/10
CXSResponse to an ASX Price QueryPRICE SENSITIVE05/10/10
CXSChemGenex Completes pre-NDA Meeting with U.S. FDAPRICE SENSITIVE05/10/10
CXSPreliminary Final ReportPRICE SENSITIVE27/08/10
CXSFDA agrees on potential regulatory pathway for OMAPROPRICE SENSITIVE14/07/10
CXSComplete Response Letter from FDA ReceivedPRICE SENSITIVE12/04/10
CXSODAC seeks validated diganostic before approval of OMAPROPRICE SENSITIVE23/03/10
CXSHalf Yearly Report and AccountsPRICE SENSITIVE25/02/10
CXSODAC Postponed Due to Extreme Weather in Washington DCPRICE SENSITIVE09/02/10
CXSOmapro ODAC meeting confirmed for 10 February 2010PRICE SENSITIVE17/12/09
CXSOmacetaxine European rights licensed to HospiraPRICE SENSITIVE14/12/09
CXSUpdated omacetaxine data from multiTKI failure studyPRICE SENSITIVE09/12/09
CXSOmapro Data Highlighted at ASH Press ConferencePRICE SENSITIVE07/12/09
CXSEMEA validates ChemGenex's MAA for omacetaxinePRICE SENSITIVE27/11/09
CXSUS FDA accepts Omapro NDA - grants priority reviewPRICE SENSITIVE10/11/09
CXSPreliminary Final ReportPRICE SENSITIVE27/08/09
CXSOmacetaxine Kills Leukemic Stem Cells in Human CML ModelsPRICE SENSITIVE09/06/09
CXSOmacetaxine Shows Activity in Refractory CMLPRICE SENSITIVE09/06/09
CXSOmacetaxine Clinical Data Presented at ASCOPRICE SENSITIVE02/06/09
CXSRights Issue Fully Subscribed, Further $1 Million PlacementPRICE SENSITIVE27/05/09
CXSInformation Booklet for ShareholdersPRICE SENSITIVE21/04/09
CXSNon-Renounceable IssuePRICE SENSITIVE21/04/09
CXSPlacement and Non-Renounceable Rights IssuePRICE SENSITIVE09/04/09
CXSReinstatement to Official QuotationPRICE SENSITIVE09/04/09
CXSSuspension from Official QuotationPRICE SENSITIVE08/04/09
CXSTrading HaltPRICE SENSITIVE06/04/09
CXSNew Data Suggests Omacetaxine Eradicates Leukemic Stem CellsPRICE SENSITIVE27/03/09
CXSHalf Yearly Report and AccountsPRICE SENSITIVE25/02/09
CXSFDA Grants Orphan Drug Designation to Omacetaxine for MDSPRICE SENSITIVE20/01/09
CXSInterim Clinical Trial Results Presented at ASH ConferencePRICE SENSITIVE09/12/08
CXSSuspension at close of trading 21/6/11
21/06/11PRICE SENSITIVE
CXSNotice of Compulsory Acquisition
14/06/11PRICE SENSITIVE
CXSNotice of Variation of Offer: Extension of Offer Period
14/06/11PRICE SENSITIVE
CXSNotice Under Sec 630(3) - Status of Defeating Conditions
06/06/11PRICE SENSITIVE
CXSNotice under Sec 650F re Cephalon T/O
01/06/11PRICE SENSITIVE
CXSExtension of Office Period
27/05/11PRICE SENSITIVE
CXSNotice under Section 650F of Corps Act
27/05/11PRICE SENSITIVE
CXSCephalon CXS Holdings PL Notice of Acceptances
27/05/11PRICE SENSITIVE
CXSSupplementary Bidder's Statement
20/05/11PRICE SENSITIVE
CXSVariation of Takeover Bid
13/05/11PRICE SENSITIVE
CXSSupplementary Bidder's Statement
04/05/11PRICE SENSITIVE
CXSFirst Supplementary Bidder's Statement
29/04/11PRICE SENSITIVE
CXSOff market takeover bid by Cephalon
27/04/11PRICE SENSITIVE
CXSBidder's Statement and Target's Statement
13/04/11PRICE SENSITIVE
CXSCephalon Update
30/03/11PRICE SENSITIVE
CXSCephalon Launches Takeover Bid
29/03/11PRICE SENSITIVE
CXSTrading Halt
25/03/11PRICE SENSITIVE
CXSHalf Yearly Report and Accounts
18/02/11PRICE SENSITIVE
CXSChemGenex to Align European and US Regulatory Strategies
05/01/11PRICE SENSITIVE
CXSAwarded U.S. Therapeutic Discovery grant
02/11/10PRICE SENSITIVE
CXSConvertible Note Issued to Cephalon, Inc
22/10/10PRICE SENSITIVE
CXSResponse to an ASX Price Query
05/10/10PRICE SENSITIVE
CXSChemGenex Completes pre-NDA Meeting with U.S. FDA
05/10/10PRICE SENSITIVE
CXSPreliminary Final Report
27/08/10PRICE SENSITIVE
CXSFDA agrees on potential regulatory pathway for OMAPRO
14/07/10PRICE SENSITIVE
CXSComplete Response Letter from FDA Received
12/04/10PRICE SENSITIVE
CXSODAC seeks validated diganostic before approval of OMAPRO
23/03/10PRICE SENSITIVE
CXSHalf Yearly Report and Accounts
25/02/10PRICE SENSITIVE
CXSODAC Postponed Due to Extreme Weather in Washington DC
09/02/10PRICE SENSITIVE
CXSOmapro ODAC meeting confirmed for 10 February 2010
17/12/09PRICE SENSITIVE
CXSOmacetaxine European rights licensed to Hospira
14/12/09PRICE SENSITIVE
CXSUpdated omacetaxine data from multiTKI failure study
09/12/09PRICE SENSITIVE
CXSOmapro Data Highlighted at ASH Press Conference
07/12/09PRICE SENSITIVE
CXSEMEA validates ChemGenex's MAA for omacetaxine
27/11/09PRICE SENSITIVE
CXSUS FDA accepts Omapro NDA - grants priority review
10/11/09PRICE SENSITIVE
CXSPreliminary Final Report
27/08/09PRICE SENSITIVE
CXSOmacetaxine Kills Leukemic Stem Cells in Human CML Models
09/06/09PRICE SENSITIVE
CXSOmacetaxine Shows Activity in Refractory CML
09/06/09PRICE SENSITIVE
CXSOmacetaxine Clinical Data Presented at ASCO
02/06/09PRICE SENSITIVE
CXSRights Issue Fully Subscribed, Further $1 Million Placement
27/05/09PRICE SENSITIVE
CXSInformation Booklet for Shareholders
21/04/09PRICE SENSITIVE
CXSNon-Renounceable Issue
21/04/09PRICE SENSITIVE
CXSPlacement and Non-Renounceable Rights Issue
09/04/09PRICE SENSITIVE
CXSReinstatement to Official Quotation
09/04/09PRICE SENSITIVE
CXSSuspension from Official Quotation
08/04/09PRICE SENSITIVE
CXSTrading Halt
06/04/09PRICE SENSITIVE
CXSNew Data Suggests Omacetaxine Eradicates Leukemic Stem Cells
27/03/09PRICE SENSITIVE
CXSHalf Yearly Report and Accounts
25/02/09PRICE SENSITIVE
CXSFDA Grants Orphan Drug Designation to Omacetaxine for MDS
20/01/09PRICE SENSITIVE
CXSInterim Clinical Trial Results Presented at ASH Conference
09/12/08PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

New Zealand’s Reserve Bank has taken a bold step, slashing rates by 50 basis points to 4.25% @ its third cut in just four months. Meanwhile, the Reserve Bank of Australia holds firm at 4.35%, its highest rate in over a decade.This stark policy divergence highlights contrasting glo...
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
HotCopper Highlights: Your most watched stocks for Week 48, 2024 Good afternoon, a happy end of the week, and welcome to HotCopper Highlights – I’m Jonathon Davidson. Let’s get into it.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.